Paul Bunn
Director/Board Member chez VERASTEM, INC.
Fortune : - $ au 31/03/2024
Profil
Paul A.
Bunn is a founding scientist and director of ApopLogic Pharmaceuticals, Inc. founded in 2006.
He is currently an independent director at Verastem, Inc. since 2021 and a professor at The University of Colorado School of Medicine.
Dr. Bunn received his undergraduate degree from Amherst College and his doctorate from Weill Cornell Medical College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
VERASTEM, INC.
-.--% | 11/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Paul Bunn
| Sociétés | Poste | Début |
|---|---|---|
| VERASTEM, INC. | Director/Board Member | 24/06/2021 |
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Founder | 01/01/2006 |
| The University of Colorado School of Medicine | Corporate Officer/Principal | - |
Anciens postes connus de Paul Bunn
| Sociétés | Poste | Fin |
|---|---|---|
| International Association for the Study of Lung Cancer | Chief Executive Officer | - |
Association of American Cancer Institutes
 Association of American Cancer Institutes Miscellaneous Commercial ServicesCommercial Services Association of American Cancer Institutes operates as a membership association of academic and freestanding cancer research centers in the United States. It comprises 98 cancer research centers. The company is headquartered in Pittsburgh, PA. | President | - |
| University of Colorado Cancer Center | Director/Board Member | - |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | President | - |
| The University of Colorado | Corporate Officer/Principal | - |
Formation de Paul Bunn
| Amherst College | Undergraduate Degree |
| Weill Cornell Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VERASTEM, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |
| International Association for the Study of Lung Cancer | |
Association of American Cancer Institutes
Association of American Cancer Institutes Miscellaneous Commercial ServicesCommercial Services Association of American Cancer Institutes operates as a membership association of academic and freestanding cancer research centers in the United States. It comprises 98 cancer research centers. The company is headquartered in Pittsburgh, PA. | Commercial Services |
